DMEMEDS shared post via Reuters: Lilly says drug slows Alzheimer's in patients with mild disease

(Reuters) - Patients with mild Alzheimer's disease who took Eli Lilly and Co's experimental drug solanezumab early in the course of their disease preserved more of their cognitive and functional ability, according to new Lilly data released on Wednesday. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/uJVHBjvU_tc/story01.htm

Read More